Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Radiation Therapy, and Axatilimab in High-Risk TNBC
NCT05491226Phase 2Recruiting
- Sponsor
- Stephen Shiao
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axatilimab in triple-negative breast cancer (TNBC), sponsored by Stephen Shiao. Primary endpoint: Pathological complete response rate at 7 weeks. Started Nov 2023; status: recruiting.
02
Drugs
axatilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05491226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491226.